Hybrid capture-based next generation sequencing
Personalized cancer therapies, based on the individual genetic tumor profile of the patient have led to a paradigm shift in oncology in recent years. An increasing number of genetic changes involved in tumor progression have been identified that can be successfully treated with targeted therapies.
The NEO technology is suitable for analyzing solid tumors regardless of the indication.
It reliably detects point mutations, small insertions and deletions, copy number alterations and translocations in oncogenes and tumor suppressors. In addition, microsatellite instability is tested in tissue samples. The analysis can be performed on routine clinical tissue samples (FFPE, cryosections, cytologies) or blood.
NEO is based on “hybrid capture-based next generation sequencing (NGS)” technology, which facilitates analysis of tumor and therapy-relevant gene segments in an efficient and time-saving multiplex procedure. This novel approach has made time-consuming single gene sequencing or fluorescence hybridization (FISH) analysis obsolete.
First, the genes of interest are extracted from the genome of the tumor using complementary probes (hybrid capture). The baits ensure optimal selection of therapy and tumor progression-relevant genes. Upon binding to the baits, all targeted fragments are amplified (clonal amplification) and sequenced in parallel.
The NEO technology includes a complete bioinformatic analysis of the sequencing data obtained. Mutations, small insertions and deletions, gene copy number alterations and translocations can be reliably identified and examined for their therapeutic relevance. The derived data provide rational decision-making support for treatment with targeted medicines.
Back to the top